Navidea Biopharmaceuticals Inc (NAVB)’s Financial Results Comparing With resTORbio Inc. (NASDAQ:TORC)

We are comparing Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) and resTORbio Inc. (NASDAQ:TORC) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Navidea Biopharmaceuticals Inc 1.45M 22.62 19.16M -0.12 0.00
resTORbio Inc. N/A 0.00 54.91M -2.06 0.00

Table 1 highlights Navidea Biopharmaceuticals Inc and resTORbio Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows us Navidea Biopharmaceuticals Inc and resTORbio Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Navidea Biopharmaceuticals Inc -1,321.38% -355.9% -119.6%
resTORbio Inc. 0.00% -67.6% -50.1%

Institutional and Insider Ownership

Roughly 6.6% of Navidea Biopharmaceuticals Inc shares are owned by institutional investors while 43.4% of resTORbio Inc. are owned by institutional investors. About 12.4% of Navidea Biopharmaceuticals Inc’s share are owned by insiders. Insiders Competitively, owned 55.61% of resTORbio Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Navidea Biopharmaceuticals Inc -25.52% -41.38% -14.85% -39.79% -67.26% -59.69%
resTORbio Inc. -3.52% 5.79% 2.61% 24.26% 0% -25.36%

For the past year Navidea Biopharmaceuticals Inc was more bearish than resTORbio Inc.


resTORbio Inc. beats Navidea Biopharmaceuticals Inc on 5 of the 9 factors.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, San Diego. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.